Literature DB >> 36031684

Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod.

Matheus Bernardon Morillos1, Paulo Henrique Pires de Aguiar2, Paulo Roberto Franceschini3, Juliana Ávila Duarte4, Cristian Daniel Piccini5, Alessandro Finkelsztejn1.   

Abstract

Primary central nervous system lymphoma (PCNSL) is an uncommon lymphoproliferative disease associated with immunosuppression. Here, we report the case of a patient with multiple sclerosis, under treatment with fingolimod (FTY720, Gilenya) for 4 years, who developed this condition. Although the causal relationship cannot be established, there are cases in the literature that describe the appearance of lymphoma after the use of this medication. Considering the high mortality of PCNSL, epidemiological studies are necessary to establish a relationship between its arising and the use of immunosuppressants.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Brain; CNS; Fingolimod; Lymphoma; Multiple sclerosis; Primary

Year:  2022        PMID: 36031684     DOI: 10.1007/s10072-022-06367-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  11 in total

Review 1.  Primary central nervous system lymphoma.

Authors:  Giovanni Citterio; Michele Reni; Gemma Gatta; Andrés José Maria Ferreri
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-18       Impact factor: 6.312

2.  Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.

Authors:  Anne Froehlich; Stephan Schmidt; Jenny Landsberg; Thomas Bieber; Joerg Wenzel
Journal:  Mult Scler       Date:  2018-05-03       Impact factor: 6.312

Review 3.  Peripheral T-cell lymphomas as fingolimod-associated lymphoproliferative disorder for patients with multiple sclerosis - case report with literature review.

Authors:  Hidetsugu Kawai; Hiromichi Matsushita; Hibiki Akashi; Daisuke Furuya; Shohei Kawakami; Rikio Suzuki; Makiko Moriuchi; Yoshiaki Ogawa; Hiroshi Kawada; Naoya Nakamura; Kiyoshi Ando
Journal:  Leuk Lymphoma       Date:  2019-11-27

4.  Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.

Authors:  Karen L Christopher; Victor M Elner; Hakan Demirci
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2017 May/Jun       Impact factor: 1.746

5.  Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.

Authors:  Joseph A Chacko; Paolo Strati; Paul W Stout; Robert L Archer; Brad P Baltz; Joseph G Chacko
Journal:  Mult Scler Relat Disord       Date:  2021-01-19       Impact factor: 4.339

6.  Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.

Authors:  Despoina Papathemeli; Ronald Gräfe; Uwe Hildebrandt; Uwe K Zettl; Jens Ulrich
Journal:  Mult Scler       Date:  2016-04-26       Impact factor: 6.312

7.  Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.

Authors:  Navid Manouchehri; Omid Mirmosayyeb; Shervin Badihian; Vahid Shaygannejad
Journal:  Mult Scler Relat Disord       Date:  2017-11-22       Impact factor: 4.339

8.  A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.

Authors:  Derek W Stitt; Christopher J Boes; Eoin P Flanagan; Matthew T Howard; Joseph P Colgan
Journal:  Mult Scler Relat Disord       Date:  2017-11-16       Impact factor: 4.339

9.  Autoimmune conditions and primary central nervous system lymphoma risk among older adults.

Authors:  Parag Mahale; Megan M Herr; Eric A Engels; Ruth M Pfeiffer; Meredith S Shiels
Journal:  Br J Haematol       Date:  2019-10-17       Impact factor: 8.615

Review 10.  An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.

Authors:  Neeta Garg; Thomas W Smith
Journal:  Brain Behav       Date:  2015-08-03       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.